Lentivirus expression vector of human Sox4, truncated HMG domain (57 aa - 133 aa).
| Clone info. | Lentivirus expression vector of human SRY-box 4 (SOX4), truncated high-mobility group (HMG) domain (57 aa - 133 aa), EF-1 alpha promoter, Venus. Please refer to Fig. 4a and b of Yoshitomi, H. et al., Nat. Commun., 9 (1): 3762, 2019. |
|---|---|
| Comment | Expression was confirmed by the deposotor with the observation of Venus expression and western blotting. |
| Vector backbone | CSIIR-EF-MCS-IRES2-Venus (RDB17308) (plasmid) |
| Size of vector backbone | 10.0 kb |
| Selectable markers | Amp^r. |
| Growth conditions | LB+Ampicillin, 37℃ |
| Gene/insert name | human SOX4 cDNA |
| Depositor|Developer | Yoshitomi, Hiroyuki | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment MTA, for use for not-for-profit academic purpose [Word Please visit Ordering instruction.[link] |
|---|---|
| Terms and conditions for distribution | In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested (Yoshitomi H. et al. Nat. Commun. 9(1), 3762, 2018). The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit organization for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit organization, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. Additional terms and conditions: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer of the lentivirus vector. Further transfer, provision of services or resale of the Zeocin resistance gene, and the Deposited Materials is prohibited without InvivoGen's prior written consent. In addition, InvivoGen's Limited Use Label License applies to your use of this product. |
| Remarks | Zeocin® is a trademark of InvivoGen registered with the United States Patent and Trademark Office and foreign equivalents. See InvivoGen Limited Use Label License. |
[open/close]| 必要書類 | 提供依頼書 提供同意書 (MTA, 非営利学術目的用)[Word 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Yoshitomi H. et al. Nat. Commun. 9(1), 3762, 2018)。学術機関の学術研究に限る。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。 付加的使用条件: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). レンチウイルスベクターについて、本件研究材料を利用した研究結果等を発表する際は、レンチウイルスベクターが故三好浩之博士により開発されたことを明示する。 InvivoGen社の事前の書面による同意がない限り、ゼオシン耐性遺伝子および寄託マテリアルの第三者への移転、サービスの提供、または再販売は禁止されています。また、ご利用に際してInvivoGen社のLimited Use Label Licenseが適用されます。 |
| 備考 | ZeocinはInvivoGen社の製品です。Zeocin®は、米国特許商標庁および米国外の同等機関に登録されたInvivoGen社の商標です。InvivoGen Limited Use Label Licenseをご確認ください。 |
| Catalog # | Resource name | Availability | Shipping form | Fee |
|---|---|---|---|---|
| RDB17313 | CSII-EF-IRES2-Venus_hSOX4 deltaHMG | Under QC test. Please contact us. | DNA solution |
Materials & Methods section:
| The CSII-EF-IRES2-Venus_hSOX4 deltaHMG was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB17313). |
Reference section:
| Yoshitomi, H., Kobayashi, S., Miyagawa-Hayashino, A., Okahata, A., Doi, K., Nishitani, K., Murata, K., Ito, H., Tsuruyama, T., Haga, H., Matsuda, S., Toguchida, J., Human Sox4 facilitates the development of CXCL13-producing helper T cells in inflammatory environments. Nat. Commun. 9 (1): 3762 (2018). PMID 30232328. [PubMed] [Article] [RRC of NBRP] |
Further references such as user reports and related articles (go to bottom)
Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.
Original, user report and related articles
| original | Yoshitomi, H., Human Sox4 facilitates the development of CXCL13-producing helper T cells in inflammatory environments. Nat. Commun. 9 (1): 3762 (2018). PMID 30232328. [PubMed] [Article] [RRC of NBRP] |
|---|
Featured content